Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Petróleo Brasileiro SA — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.21 (market cap $2.81B), while Petróleo Brasileiro SA trades at $25.67 (market cap $159.16B). The key difference: Petróleo Brasileiro SA is far larger — about 56.6× Dyne Therapeutics Inc. Common Stock's market cap, and Petróleo Brasileiro SA pays a 6.46% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Petróleo Brasileiro SA for 26 Days on average.
| DYN | PBR | |
|---|---|---|
Market Cap | $2.81B | $159.16B |
Volume | 2,195,902 | 19,717,211 |
Sector | Health | Energy |
52-Week High | $26.78 | $25.94 |
52-Week Low | $14.60 | $11.54 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $2.13B | $219.58B |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
PBR trades at $25.66, up 0.61% with strong technical momentum as moving averages signal bullish sentiment. The stock shows robust fundamentals with a P/E of 6.55, net income margin of 24.52%, and ROE of 30.77%. Recent positive developments include new oil discoveries and platform deployments, while Q2 2026 earnings beat expectations by 15%.
PBR presents compelling value with attractive valuation multiples and strong profitability. Key risks include capital expenditure volatility and political exposure in Brazil. Analyst consensus leans bullish with 50% buy ratings, though the $22.33 price target suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
